XTX Topco Ltd Sells 2,130 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

XTX Topco Ltd lowered its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 6.2% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 32,272 shares of the company’s stock after selling 2,130 shares during the period. XTX Topco Ltd’s holdings in Amneal Pharmaceuticals were worth $205,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in AMRX. Rothschild Investment LLC bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $26,000. DekaBank Deutsche Girozentrale bought a new position in Amneal Pharmaceuticals in the second quarter worth $42,000. nVerses Capital LLC acquired a new stake in Amneal Pharmaceuticals during the second quarter worth $62,000. Atlanta Consulting Group Advisors LLC bought a new stake in Amneal Pharmaceuticals in the 1st quarter valued at $61,000. Finally, Trexquant Investment LP acquired a new position in shares of Amneal Pharmaceuticals in the 4th quarter valued at $65,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock opened at $8.19 on Monday. The stock has a market capitalization of $2.53 billion, a price-to-earnings ratio of -14.63 and a beta of 1.18. The firm’s 50-day moving average price is $8.05 and its two-hundred day moving average price is $6.99. The company has a current ratio of 1.33, a quick ratio of 0.82 and a debt-to-equity ratio of 121.31. Amneal Pharmaceuticals, Inc. has a 1-year low of $3.36 and a 1-year high of $8.90.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Friday, August 9th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.04. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. The business had revenue of $701.78 million for the quarter, compared to analyst estimates of $657.43 million. On average, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on AMRX. Truist Financial lifted their target price on shares of Amneal Pharmaceuticals from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Barclays upped their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a research report on Friday, September 6th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $9.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.